scholarly article | Q13442814 |
P356 | DOI | 10.1177/0961203310395803 |
P698 | PubMed publication ID | 21303837 |
P50 | author | Munther A. Khamashta | Q73418907 |
Guillermo Ruiz-Irastorza | Q37830875 | ||
Vittorio Pengo | Q42778559 | ||
Maria G Tektonidou | Q57034988 | ||
P2093 | author name string | S Machin | |
M Crowther | |||
D Erkan | |||
R Brey | |||
S Krilis | |||
M J Cuadrado | |||
S Pierangeli | |||
R Derksen | |||
I Ruiz-Arruza | |||
P433 | issue | 2 | |
P921 | main subject | thrombosis | Q261327 |
P304 | page(s) | 206-218 | |
P577 | publication date | 2011-02-01 | |
P1433 | published in | Lupus | Q6704846 |
P1476 | title | Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | |
P478 | volume | 20 |
Q54982015 | A case of extreme weight loss due to mesenteric ischemia and antiphospholipid syndrome. |
Q90446471 | A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review |
Q55279180 | A importância de reconhecer a síndrome antifosfolípide na medicina vascular. |
Q96306532 | ADRENAL INSUFFICIENCY SECONDARY TO BILATERAL ADRENAL HEMORRHAGE ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME |
Q96304889 | An update on the management of antiphospholipid syndrome |
Q92639094 | Anaesthetic considerations for patients with antiphospholipid syndrome undergoing non-cardiac surgery |
Q30355477 | Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio. |
Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
Q33768066 | Antiphospholipid Syndrome: Multiple Manifestations in a Single Patient-A High Suspicion Is Still Needed |
Q46466244 | Antiphospholipid antibodies in renal allograft recipients. |
Q52368982 | Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. |
Q93140231 | Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events? |
Q30235423 | Antiphospholipid syndrome |
Q64046338 | Antiphospholipid syndrome |
Q91390119 | Antiphospholipid syndrome - an update |
Q58602902 | Antiphospholipid syndrome: state of the art on clinical practice guidelines |
Q57689029 | Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies |
Q94327168 | Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies |
Q24185949 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome |
Q47884958 | Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. |
Q47093647 | Cavernous sinus thrombosis in a patient with nephrotic syndrome. |
Q38686357 | Childhood Lupus--Diagnosis and Management |
Q60949185 | Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome |
Q97426362 | Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review |
Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
Q33421814 | Difficult clinical situations in the antiphospholipid syndrome |
Q51252221 | Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. |
Q38089684 | Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? |
Q58783569 | Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report |
Q22306331 | Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association |
Q36087118 | Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis |
Q90115791 | Idiopathic Normal Pressure Hydrocephalus - What We Know |
Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
Q57115414 | Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure |
Q37522782 | Improving outcomes in patients with lupus and end-stage renal disease |
Q97520328 | Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates |
Q34462703 | Inferior vena cava filters: current best practices |
Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
Q37977481 | Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment |
Q48328781 | Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study |
Q36033553 | Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome |
Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
Q37959314 | Management of obstetric antiphospholipid syndrome |
Q38180647 | Management of recurrent thrombosis in antiphospholipid syndrome |
Q49968681 | Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome |
Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
Q58551653 | Obstetric antiphospholipid syndrome |
Q89986376 | Pediatric APS: State of the Art |
Q41100232 | Pediatric antiphospholipid syndrome |
Q89724842 | Precision medicine and the antiphospholipid syndrome: what is the future? |
Q90115787 | Pregnancy Management in Women with Antiphospholidic Syndrome |
Q60954866 | Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria |
Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
Q39027911 | Prevention of thrombosis in antiphospholipid syndrome |
Q52649404 | Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia. |
Q64088190 | Recurrent Stroke Due to Antiphospholipid Syndrome Remitted by Immunotherapy, Not by Anticoagulation Therapy: A Case Report and Literature Review |
Q89777587 | Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy |
Q55710004 | Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. |
Q87467570 | Renal involvement in antiphospholipid syndrome |
Q38838855 | Renal involvement in primary antiphospholipid syndrome |
Q38374309 | Reviewing the recommendations for lupus in children |
Q33428599 | Right Atrial Thrombosis in Antiphospholipid Syndrome with Secondary Immune Thrombocytopenia |
Q37230504 | Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial |
Q89924903 | Role of direct oral anticoagulants in patients with kidney disease |
Q26775647 | Sarcoidosis and Antiphospholipid Syndrome: A Systematic Review of Cases |
Q89453447 | Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management |
Q45168417 | Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis |
Q38097749 | Statins and autoimmunity |
Q92737863 | Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome |
Q55282858 | Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. |
Q59807283 | The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome |
Q96135566 | The Issue of the Antiphospholipid Antibody Syndrome |
Q38374306 | The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome |
Q37959884 | The management of stroke in antiphospholipid syndrome |
Q50906356 | The significance of antiphospholipid antibodies in liver recipients. |
Q37347979 | Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics |
Q36981341 | Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus |
Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
Q35308972 | Treatment of the antiphospholipid syndrome |
Q93047783 | Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies |
Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
Q35187737 | Venous thromboembolism and antithrombotic therapy in pregnancy |
Q90416101 | [Antiphospholipid syndrome : Update on diagnostics and management] |
Q87078561 | [Antiphospholipid syndrome] |
Q87831212 | [Antiphospholipid syndrome] |
Q86911419 | [Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke] |
Search more.